No data available
VCLS is a global product development consultancy, which guides Biotechnology, Medtech, and Pharmaceutical manufacturers throughout product development and commercialization. From discovery to patients, VCLS assists innovators to design product development strategies that optimize clinical development to drive commercial success, through an understanding of both regulators and payers.
VCLS’s team of HealthTech product specialists seamlessly complement innovative life sciences companies’ resources with strategic advice and cross-functional operational capabilities. The firm offers integrated solutions to development planning, manufacturing, quality and controls, nonclinical and clinical testing, safety monitoring, and interactions with regulators and payers. With offices in Cambridge, Somerville (MA & NJ, USA), London (UK), Paris and Rennes (France), Lausanne (Switzerland), Copenhagen (Denmark) and Bangalore (India). VCLS serves a broad range of developers and investors.
VCLS’s team of HealthTech product specialists seamlessly complement innovative life sciences companies’ resources with strategic advice and cross-functional operational capabilities. The firm offers integrated solutions to development planning, manufacturing, quality and controls, nonclinical and clinical testing, safety monitoring, and interactions with regulators and payers. With offices in Cambridge, Somerville (MA & NJ, USA), London (UK), Paris and Rennes (France), Lausanne (Switzerland), Copenhagen (Denmark) and Bangalore (India). VCLS serves a broad range of developers and investors.
Our research at the Wellcome Trust Sanger Institute builds understanding of gene function in health and disease as well as creating resources of lasting value to biomedical research. . . We study diseases that have an impact on health globally by investigating genomes. Building on our past achievements and based on priorities that exploit the unique expertise of our Faculty of researchers, we will lead global efforts to understand the biology of genomes. We are convinced of the importance of making this research available and accessible for all audiences.
Choosing the right patent attorney to protect your valuable intellectual property can be a daunting task. Withers and Rogers is one of the foremost providers of intellectual property protection services in the United Kingdom and Europe. Each Withers and Rogers attorney is selected on the basis of excellent academic achievement and industry knowledge. When choosing a UK patent attorney or trade mark attorney, we hope you will consider us for our experience, client focus and professionalism. . . Withers & Rogers has a breadth and depth of experience and expertise that we believe is second to none. In addition to our practice groups, we have a number of specialist groups, enabling us to pool our industry knowledge and bring added value for our clients. . . How we work. We start by understanding your needs and helping you to maximise the success of your products, services and brands through the effective use of intellectual property. In a commercial world, we understand that you are looking for efficient and effective intellectual property strategies, backed by practical advice and support. This is always our priority. . . Principal practice groups . •Life Sciences and Chemistry group . •Advanced Engineering group . •Electronics Computing and Physics group . •Trade Mark group
WuXi AppTec is a leading open-access R&D capability and technology platform with operations in China, USA, Germany and Iceland. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities in small molecule, biologics, cell therapy and gene therapy, medical device testing, and molecular testing and genomics, WuXi is enabling more than 2000 collaborators from more than 30 countries to bring innovative healthcare products to patients.
Xampla is the leader in the development of plant protein materials
We take our inspiration, and our name, from the principle of exaptation – the concept that a trait which evolved for one purpose can be harnessed to serve an entirely different function.
Using the power of genome editing and synthetic biology, we’ve converted nature’s ultimate first-responder cell into a modular chassis, ready to be programmed to treat disease. We’re arming our delivery platform to carry a broad spectrum of therapeutic payloads – cytokines, antibodies, nucleic acids and more. We’ve designed these delivery vehicles to activate only on recognition of their chosen targets, unleashing their powerful cargo with exquisite precision.
We’re developing our multi-modal therapies to treat the most complex of diseases including cancer and autoimmunity.
Using the power of genome editing and synthetic biology, we’ve converted nature’s ultimate first-responder cell into a modular chassis, ready to be programmed to treat disease. We’re arming our delivery platform to carry a broad spectrum of therapeutic payloads – cytokines, antibodies, nucleic acids and more. We’ve designed these delivery vehicles to activate only on recognition of their chosen targets, unleashing their powerful cargo with exquisite precision.
We’re developing our multi-modal therapies to treat the most complex of diseases including cancer and autoimmunity.